๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT05563844Diffuse Large B Cell Lymphoma๏ผŒDLBCL
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
74
Shanghai, Chengdu
2022-11-08
Recruiting
Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial
NCT05326932Acute Ischemic Stroke
Fudan University
Not applicable
336
Shanghai
2022-11-03
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
DrugsEntrectinib·Alectinib·Durvalumab
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
NCT06122493Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2
48
Shanghai
2022-11-01
Recruiting
Pre-operative Therapy in Breast Cancer
NCT05621564Breast Cancer
RenJi Hospital
Observational
6,032
Shanghai
2022-11-01
Recruiting
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NCT05494190Hypopharyngeal Carcinoma
DrugsDocetaxel·Capecitabine·Cisplatin
Eye & ENT Hospital of Fudan University
Not applicable
111
Harbin, Jinan, Shanghai
2022-11-01
Recruiting
The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma
NCT05496582Asthma
Shanghai University of Traditional Chinese Medicine
Observational
100
Changsha, Shanghai
2022-11-01
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
DrugsSHR-4602·TQB2868·HRS-4508·IBI354
Fudan University
Phase 2
716
Shanghai
2022-11-01
By invitation
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
NCT05844813Retroperitoneal Sarcoma
DrugsIfosfamide·Doxorubicin
Peking University International Hospital
Phase 4
102
Beijing, Qingdao, Shanghai, Xiโ€™an
2022-11-01
Recruiting
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
NCT07045571Pancreatic Neoplasm, Pancreas Cancer
Yingbin Liu, MD, PhD, FACS
Observational
1,000
Shanghai
2022-10-30
By invitation
The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study
NCT05508633Portal Hypertension
Shanghai Changzheng Hospital
Phase 2
20
Shanghai
2022-10-28
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Beijing, Shanghai
2022-10-25
Recruiting
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT06617000HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
DrugSCG101
SCG Cell Therapy Pte. Ltd.
Phase 1
38
Beijing, Guangzhou, Zhengzhou, Changchun, Shenyang, Ji'nan, Shanghai
2022-10-25
Active, closed
Acute Health Effects of High Temperature Exposure
NCT05575752Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
30
Shanghai
2022-10-23
Active, closed
Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia
NCT05510700Breast Neoplasms, Insomnia
Yin Ping
Not applicable
264
Shanghai
2022-10-20
Recruiting
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
NCT05668884Biliary Tract Carcinoma
Fudan University
Phase 2
93
Shanghai
2022-10-18
Active, closed
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study
NCT05586100Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
52
Shanghai
2022-10-13
Recruiting
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
NCT05271916Non-Small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital
Phase 1/2
140
Shanghai
2022-10-13
Active, closed
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
NCT06588569Primary Liver Cancer, Colorectal Cancer Liver Metastases
Fudan University
Not applicable
20
Shanghai
2022-10-12
Recruiting
Combined Immunosuppression for Pediatric Crohn's Disease
NCT05043870Crohn Disease, Infliximab, Immunosuppression, Children, Only
DrugInfliximab
Children's Hospital of Fudan University
Phase 4
128
Shanghai
2022-10-10
Recruiting
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
NCT07632365Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
Shanghai Chest Hospital
Phase 1/2
108
Shanghai
2022-10-09
Active, closed
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
NCT05509790Breast Neoplasms
DrugImlunestrant
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Beijing, Shanghai, Tianjin
2022-10-03
Recruiting
PK/PD of Caspofungin in Children Severe Infection
NCT04961593Pharmacokinetics, Infection, Fungal
DrugCaspofungin
Children's Hospital of Fudan University
Observational
60
Shanghai
2022-10-01
Not yet open
Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese
NCT05435898Cardiovascular Diseases, Cardiovascular Morbidity, Subclinical Organ Damage, Digital Health
Shanghai 10th People's Hospital
Observational
4,000
Shanghai
2022-10-01
Recruiting
PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection
NCT04961580Sepsis, Antibiotic Reaction
Children's Hospital of Fudan University
Observational
30
Shanghai
2022-10-01
Recruiting
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
NCT05292404Acute Myocardial Infarction
DrugAlirocumab
Shanghai Tong Ren Hospital
Phase 4
160
Shanghai
2022-10-01
Recruiting
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
NCT05575804Advanced/ Metastatic Her-2 Positive Breast Cancer
Fudan University
Phase 1/2
32
Shanghai
2022-10-01
Recruiting
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
NCT04973293Lung Neoplasm Malignant
Ruijin Hospital
Not applicable
20
Shanghai
2022-10-01
Recruiting
Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
NCT05537129Gastric Cancer
Fudan University
Not applicable
600
Shanghai
2022-10-01
Recruiting
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
NCT05557552Non-small Cell Lung Cancer Stage III
Ruijin Hospital
Not applicable
56
Shanghai
2022-09-30
Recruiting
Cell Free DNA in Mature B-cell Lymphoma
NCT04088422Mature B-Cell Lymphoma
Ruijin Hospital
Observational
320
Shanghai
2022-09-28
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
DrugSatralizumab
Hoffmann-La Roche
Phase 3
122
Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou
2022-09-27
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900Coronary Artery Disease, Acute Coronary Syndrome
CoreAalst BV
Phase 4
2,500
Shanghai, Shandong, Sichuan
2022-09-22
Active, closed
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT05533463Advanced KRAS G12D Mutant Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
102
Shanghai
2022-09-21
Active, closed
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
NCT06699524Hepatocellular Carcinoma
Shen Feng
Observational
122
Shanghai
2022-09-20
Recruiting
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
NCT05482568Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Recruiting
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
NCT05360290Breast Cancer, Circulating Tumor Cell
RenJi Hospital
Not applicable
484
Shanghai
2022-09-14
Active, closed
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
NCT05621486Advanced Solid Tumor
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Active, closed
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
NCT05531123Bladder Cancer
DrugsGemcitabine and cisplatin·Tislelizumab
Fudan University
Phase 2
30
Shanghai
2022-09-10
Recruiting
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
NCT04728724Non-small Cell Lung Cancer Stage III
DrugSintilimab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2022-09-10
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
DrugDepemokimab
GlaxoSmithKline
Phase 3
109
Beijing, Changsha, Guangzhou, Harbin, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
NCT05536102Gastric Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
38
Shanghai
2022-09-05
Active, closed
The Rechallenge of ADCs in MBC Patients
NCT05571618Breast Cancer
Fudan University
Observational
100
Shanghai
2022-09-01
Recruiting
Effect of Electroacupuncture on Obesity
NCT05237089Obesity
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
256
Shanghai
2022-09-01
Recruiting
Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb
NCT05286710Deep Vein Thrombosis
RenJi Hospital
Not applicable
160
Shanghai
2022-09-01
Recruiting
Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI
NCT05533060Traumatic Brain Injury
Shanghai 6th People's Hospital
Observational
200
Shanghai
2022-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Recruiting
Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma
NCT05563922Rectal Cancer
Shanghai Zhongshan Hospital
Phase 2
56
Shanghai
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Not yet open
Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment
NCT05485025Subjective Cognitive Impairment
Ruijin Hospital
Not applicable
134
Shanghai
2022-09
Recruiting
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
NCT05240950Colorectal Cancer, Metastatic Liver Cancer
Changhai Hospital
Phase 1
18
Shanghai
2022-08-25
Recruiting
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
NCT05774275High-Risk Localized Soft Tissue Sarcoma
Fudan University
Phase 1/2
52
Shanghai
2022-08-25
Recruiting
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
NCT05512286Breast Cancer
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
A Prospective Observation Registry Study on the Alimentary Reconstruction After Radical Proximal Gastrectomy
NCT05539105Proximal Gastric Adenocarcinoma, Reconstruction
Shanghai Zhongshan Hospital
Observational
600
Shanghai
2022-08-22
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Recruiting
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma๏ผˆKeyplus-001๏ผ‰
NCT05357651Solid Tumor, Lymphoma
DrugLB1410
L & L Bio Co., Ltd., Ningbo, China
Phase 1
100
Shanghai
2022-08-12
Recruiting
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348Breast Cancer, Solid Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Active, closed
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
NCT05320692Hepatocellular Carcinoma
DrugsTACE·Apatinib Mesylate·Camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Recruiting
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
NCT05306132Advanced Solid Tumor
DrugsASK120067·ASKC202
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
A Exploratory Study of Vฮณ2Vฮด2 T Lymphocyte-based Immunotherapy for MDR-TB
NCT05493267MDR-TB, Immunotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531Bladder Cancer, Non Muscle Invasive
DrugDocetaxel
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Active, closed
Pre-operative Surgical Difficulty Stratification Using Predicted Tumor Perfusion and Consistency
NCT06664190Pituitary Adenoma
Huashan Hospital
Observational
200
Shanghai
2022-08-01
Recruiting
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
NCT05447208Preimplantation Genetic Testing, Growth Hormone, Age, Parental
ShangHai Ji Ai Genetics & IVF Institute
Phase 3
400
Shanghai
2022-08-01
Recruiting
The Combination of Radiotherapy๏ผŒSurufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
NCT05839275High-Risk Localized Soft Tissue Sarcoma
Fudan University
Phase 1/2
52
Shanghai
2022-08-01
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
Fudan University
Phase 2
94
Shanghai
2022-08-01
Recruiting
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
NCT06827678Alzheimer Disease, Positron Emission Tomography
Huashan Hospital
Observational
3,000
Shanghai
2022-08-01
Active, closed
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
NCT05306028Pancretic Cancer, Diabete Mellitus
Fudan University
Phase 2
20
Shanghai
2022-08-01
Recruiting
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
NCT05306509Solid Tumor, Hematological Malignancies
Children's Hospital of Fudan University
Not applicable
120
Shanghai
2022-08-01
Recruiting
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
NCT06870942HCC - Hepatocellular Carcinoma, Radiotherapy
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Correlation Between Postoperative Cognitive-related Adverse Reactions and Brain Metabolomic Characteristics in Elderly Patients
NCT05555693POCD - Postoperative Cognitive Dysfunction
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Observational
200
Shanghai
2022-07-27
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsIbrutinib·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Recruiting
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348Myasthenia Gravis, Generalized
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
DrugsMepolizumab·Depemokimab
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Atezolizumab
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
NCT06379113Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Active, closed
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
NCT06390904Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugBevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
NCT05316935Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
DrugsGnRHa·Letrozole
Xiaojun Chen
Phase 2/3
80
Shanghai
2022-07-13
Recruiting
Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM
NCT05594797Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase 2
100
Shanghai, Wenzhou
2022-07-12
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
609
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733Biliary Atresia
DrugOdevixibat
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Recruiting
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
NCT05300269Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
73
Shanghai
2022-07-05
Active, closed
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 1
9
Beijing, Shanghai
2022-07-02
Recruiting
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
NCT05628922Nasopharyngeal Cancer
Fudan University
Phase 2
198
Shanghai
2022-07-02
Recruiting
Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
NCT05424159Pancreatic Cancer Non-resectable
Shanghai Proton and Heavy Ion Center
Not applicable
48
Shanghai
2022-07-01
Active, closed
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133TNBC
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Acupoint Application With Yanqing Zhitong Ointment for Chronic Non-specific Low Back Pain
NCT06102291Non-specific Low Back Pain
ZhanYJ
Not applicable
150
Shanghai
2022-07-01
Recruiting
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039Breast Neoplasms
Fudan University
Observational
20,000
Shanghai
2022-07-01
Not yet open
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
NCT05420480Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Not applicable
323
Shanghai
2022-07-01
Not yet open
Observation of the Natural Course of Age-related Macular Degeneration
NCT05418231Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai
2022-07
Recruiting
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682Triple-negative Breast Cancer
DrugsAK131·Efavirenz·Mecapegfilgrastim·SHR-A2102
Fudan University
Phase 2
80
Shanghai
2022-06-30
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Rows per page Showing 3201–3300 of 3827
Previous 31 32 33 34 35 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=33

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.